Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Newly Funded Health Records Database Will Boost Japan's Pharmacovigilance

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese Ministry of Health, Labor and Welfare had to rely on EU and U.S. regulators for Actos safety data concerning bladder cancer risk.

You may also be interested in...



EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective

Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.

Japan To Pass Bill For Special Economic Zones To Boost Foreign Investment And Consumer Confidence

TOKYO - Japan's Diet will pass legislation June 20 to create special economic zones in Northern Japan as part of the reconstruction effort from the March 11 earthquake and ensuing tsunami and nuclear crisis. While the specifics for the economic zones have yet to be settled, it is expected that substantial tax breaks will be included in the incentives to encourage reconstruction and foreign investment

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel